breast cancer and glp 1 drugs for Glucagon-like peptide 1 receptor agonists cancer risk: advancing precision GLP-1 Receptor Agonists in Breast – GLP-1 Drugs and Breast Cancer:

Current evidence, including magnetic resonance imaging studies, suggests that skeletal muscle alterations resulting from GLP-1 RA-induced weight loss, such as enhanced insulin sensitivity and reduced muscle fat infiltration, are adaptive, thereby improving muscle quality despite concurrent reductions in lean mass [112]

Abstract Prodrugs are derivatives with superior properties compared with the parent active pharmaceutical ingredient (API), which undergo biotransformation after administration to generate the API in situ

These adaptations may improve treatment tolerance and outcomes

placebo-controlled insomnia data exists but results are inconsistent